Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Sees 7-Percent Q3 Revenue Growth as Profits Rise 7 Percent

The net income that originally appeared in this article reported earnings for the 9-month period ended Sept. 30 and showed a 2-percent increase year over year. The story has been corrected to reflect profit for the three months ended Sept. 30, which reflect a 7-percent increase.
 
NEW YORK (GenomeWeb News) — Sigma-Aldrich today said that third-quarter revenue increased 7 percent as R&D spending grew and profit inched up 7 percent.
 
Total receipts for the three months ended Sept. 30 increased to $441.4 million from $412 million year over year.
 
“Benefits from the ongoing, global roll-out of new customer centric programs were partially offset by lower than expected improvements in underlying market conditions, particularly in Japan, and by slower than anticipated acceptance of several of our new and innovative Research Biotech products,” CEO Jai Nagarkatti said in a statement.
 
R&D spending rose slightly to $13.2 million.
 
Net income for the period increased to $68.4 million from $63.9 million last year.
 
Sigma said it had around $137 million in cash and equivalents.
 
Sigma said it expects full-year revenue from sales to increase 7 percent year over year, which will include a benefit from the acquisition in February of the JRH cell culture business. It expects organic sales growth to be around 6 percent.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.